Use of Corticosteroids in Myasthenia Gravis: Expert Opinion for Daily Management
The panel concludes that, in the near future, therapeutic strategies based on the use drugs with better tolerability and potentially lower direct and indirect costs, will be necessary.
Authors
- Matteo Gastaldi (ORCID: https://orcid.org/0000-0003-2288-2000)
- Elena Pegoraro (ORCID: https://orcid.org/0000-0002-7740-4156)
- Renato Mantegazza (ORCID: https://orcid.org/0000-0002-9810-5737)
- Francesco Habetswallner
- Carmelo Rodolico (ORCID: https://orcid.org/0000-0003-2543-6356)
- Michelangelo Maestri (ORCID: https://orcid.org/0000-0003-0960-4938)
- Rocco Liguori (ORCID: https://orcid.org/0000-0002-1815-1013)
- Giovanni Antonini (ORCID: https://orcid.org/0000-0002-7519-7739)
- Barbara Polistena (ORCID: https://orcid.org/0000-0002-0138-0223)
Institutions
- University of Pisa (IT)
- University of Messina (IT)
- University of Rome Tor Vergata (IT)
- University of Padua (IT)
- Saint Camillus International University of Health and Medical Sciences (IT)
- Fatebenefratelli Hospital (IT)
- Institute of Neurological Sciences (IT)
- Fondazione IRCCS Istituto Neurologico Carlo Besta (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-08-05
- DOI
- https://doi.org/10.1007/s40120-025-00796-w
- Citations
- 5
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 6.95